Glaukos Announces Participation in William Blair Growth Stock Conference

SAN CLEMENTE, Calif.--()--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the William Blair Growth Stock Conference on Tuesday, June 13, 2017, at 10:50 a.m. CDT in Chicago, IL.

A live audio webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012 and is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. The company believes the iStent, measuring 1.0 mm long and 0.33 mm wide, is the smallest medical device ever approved by the FDA.

Contacts

Glaukos Corporation
Sheree Aronson
VP, Investor Relations
(949) 367-9600 ext 371
saronson@glaukos.com

Contacts

Glaukos Corporation
Sheree Aronson
VP, Investor Relations
(949) 367-9600 ext 371
saronson@glaukos.com